<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<w:document xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:r="http://schemas.openxmlformats.org/officeDocument/2006/relationships" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:w="http://schemas.openxmlformats.org/wordprocessingml/2006/main" xmlns:w10="urn:schemas-microsoft-com:office:word" xmlns:wp="http://schemas.openxmlformats.org/drawingml/2006/wordprocessingDrawing"><w:body><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:b/><w:i/><w:u w:val="single"/></w:rPr></w:pPr><w:r><w:rPr><w:b/><w:i/><w:u w:val="single"/></w:rPr></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>Breast Cancer Prevention in Women with a BRCA1 or BRCA2 Mutation</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:vertAlign w:val="superscript"/></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>Kelly A. Metcalfe</w:t></w:r><w:r><w:rPr><w:vertAlign w:val="superscript"/></w:rPr><w:t>1,2</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> &amp; Steven A. Narod</w:t></w:r><w:r><w:rPr><w:vertAlign w:val="superscript"/></w:rPr><w:t>2</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr><w:vertAlign w:val="superscript"/></w:rPr><w:t>1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve">Faculty of Nursing, University of Toronto; </w:t></w:r><w:r><w:rPr><w:vertAlign w:val="superscript"/></w:rPr><w:t>2</w:t></w:r><w:r><w:rPr></w:rPr><w:t>Women’s College Hospital, Toronto, Ontario</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:vertAlign w:val="superscript"/></w:rPr></w:pPr><w:r><w:rPr><w:vertAlign w:val="superscript"/></w:rPr></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:pageBreakBefore/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:b/><w:u w:val="single"/></w:rPr></w:pPr><w:r><w:rPr><w:b/><w:u w:val="single"/></w:rPr><w:t>Introduction</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t xml:space="preserve">Genetic testing for BRCA1 and BRCA2 mutations has been available for over ten years.  Using this technology, we are able to identify women who are at significantly increased risk of developing breast and ovarian cancer.  Over the past decade, several advances have been made in the area of cancer prevention. Ultimately, the value of genetic testing for BRCA1 and BRCA2 mutations comes from reducing the number of women who develop breast cancer and the number of women dying of the disease.  For BRCA1 carriers, the estimated cumulative risks to age 70 years are 65% for breast cancer and 39% for ovarian cancer.  The corresponding risks for BRCA2 carriers are 45% for breast cancer and 11% for ovarian cancer </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Antoniou&lt;/Author&gt;&lt;Year&gt;2003&lt;/Year&gt;&lt;RecNum&gt;654&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;12677558&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;72&lt;/VOLUME&gt;&lt;NUMBER&gt;5&lt;/NUMBER&gt;&lt;YEAR&gt;2003&lt;/YEAR&gt;&lt;DATE&gt;May&lt;/DATE&gt;&lt;TITLE&gt;Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies&lt;/TITLE&gt;&lt;PAGES&gt;1117-30&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Cancer Research U.K. Genetic Epidemiology Unit, Department of Public Health, University of Cambridge, Cambridge, United Kingdom.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Antoniou, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Pharoah, P. D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Risch, H. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Eyfjord, J. E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hopper, J. L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Loman, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olsson, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Johannsson, O.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Borg, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Pasini, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Radice, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Manoukian, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Eccles, D. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tang, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olah, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Anton-Culver, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Warner, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lubinski, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Gronwald, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Gorski, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tulinius, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Thorlacius, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Eerola, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Nevanlinna, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Syrjakoski, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kallioniemi, O. P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Thompson, D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Evans, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Peto, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lalloo, F.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Evans, D. G.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Easton, D. F.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Am J Hum Genet&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Age Distribution&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Cohort Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Family&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Screening/statistics &amp;amp; numerical data&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Incidence&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Male&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/epidemiology/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Pedigree&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Assessment&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;World Health&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12677558&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="0" w:name="__Fieldmark__3_563349056"/><w:r><w:rPr></w:rPr><w:t>[1]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="0"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> (in comparison, the average woman in the general population has an 11 percent lifetime risk of developing breast cancer and a 1.5 percent risk of developing ovarian cancer).  After the initial diagnosis of breast cancer in a </w:t></w:r><w:r><w:rPr><w:i/><w:iCs/></w:rPr><w:t>BRCA1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> or </w:t></w:r><w:r><w:rPr><w:i/><w:iCs/></w:rPr><w:t>BRCA2</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> carrier, the risk of cancer in the opposite breast is approximately 3% per year.</w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Metcalfe&lt;/Author&gt;&lt;Year&gt;2004&lt;/Year&gt;&lt;RecNum&gt;655&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;15197194&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;22&lt;/VOLUME&gt;&lt;NUMBER&gt;12&lt;/NUMBER&gt;&lt;YEAR&gt;2004&lt;/YEAR&gt;&lt;DATE&gt;Jun 15&lt;/DATE&gt;&lt;TITLE&gt;Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers&lt;/TITLE&gt;&lt;PAGES&gt;2328-35&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Centre for Research on Women&amp;apos; s Health, Women&amp;apos;s College Hospital, Toronto, Ontario, Canada.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Metcalfe, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch, H. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ghadirian, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tung, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olivotto, I.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Warner, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olopade, O. I.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Eisen, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Weber, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;McLennan, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Sun, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Foulkes, W. D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;J Clin Oncol&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Age of Onset&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*genetics/*pathology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Predisposition to Disease&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasms, Second Primary/*epidemiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovariectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Prospective Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Tamoxifen/therapeutic use&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15197194&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Verhoog&lt;/Author&gt;&lt;Year&gt;2000&lt;/Year&gt;&lt;RecNum&gt;720&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;10917555&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;83&lt;/VOLUME&gt;&lt;NUMBER&gt;3&lt;/NUMBER&gt;&lt;YEAR&gt;2000&lt;/YEAR&gt;&lt;DATE&gt;Aug&lt;/DATE&gt;&lt;TITLE&gt;Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer&lt;/TITLE&gt;&lt;PAGES&gt;384-6&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Family Cancer Clinic, Department of Medical Oncology, Daniel den Hoed Cancer Centre, University Hospital Rotterdam, The Netherlands.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Verhoog, L. C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Brekelmans, C. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Seynaeve, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Meijers-Heijboer, E. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Klijn, J. G.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Br J Cancer&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Age of Onset&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged, 80 and over&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*epidemiology/*etiology/genetics/mortality&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA1/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Incidence&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasms, Second Primary/epidemiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Netherlands/epidemiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Survival Rate&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=10917555&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Robson&lt;/Author&gt;&lt;Year&gt;1998&lt;/Year&gt;&lt;RecNum&gt;721&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;9586873&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;16&lt;/VOLUME&gt;&lt;NUMBER&gt;5&lt;/NUMBER&gt;&lt;YEAR&gt;1998&lt;/YEAR&gt;&lt;DATE&gt;May&lt;/DATE&gt;&lt;TITLE&gt;BRCA-associated breast cancer in young women&lt;/TITLE&gt;&lt;PAGES&gt;1642-9&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. robsonm@mskcc.org&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Robson, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Gilewski, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Haas, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Levin, D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Borgen, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Rajan, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hirschaut, Y.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Pressman, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Rosen, P. P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lesser, M. L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Norton, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Offit, K.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;J Clin Oncol&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Age of Onset&lt;/KEYWORD&gt;&lt;KEYWORD&gt;BRCA2 Protein&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/chemistry/*genetics/mortality/pathology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Disease-Free Survival&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA1/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, Tumor Suppressor/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Germ-Line Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Jews/genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Lymphatic Metastasis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasm Proteins/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Prognosis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Receptors, Estrogen/analysis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Sequence Analysis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Survival Rate&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Transcription Factors/*genetics&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=9586873&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="1" w:name="__Fieldmark__4_563349056"/><w:r><w:rPr></w:rPr><w:t>[2-4]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="1"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.   About one in 200 women in North America carries a BRCA1 or BRCA2 mutation </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Claus&lt;/Author&gt;&lt;Year&gt;1991&lt;/Year&gt;&lt;RecNum&gt;722&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;1990835&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;48&lt;/VOLUME&gt;&lt;NUMBER&gt;2&lt;/NUMBER&gt;&lt;YEAR&gt;1991&lt;/YEAR&gt;&lt;DATE&gt;Feb&lt;/DATE&gt;&lt;TITLE&gt;Genetic analysis of breast cancer in the cancer and steroid hormone study&lt;/TITLE&gt;&lt;PAGES&gt;232-42&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Claus, E. B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Risch, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Thompson, W. D.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Am J Hum Genet&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Alleles&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Case-Control Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Disease Susceptibility&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Hormones/*metabolism&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Neoplastic Syndromes, Hereditary&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Steroids/*metabolism&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=1990835&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Whittemore&lt;/Author&gt;&lt;Year&gt;1997&lt;/Year&gt;&lt;RecNum&gt;723&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;9042908&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;60&lt;/VOLUME&gt;&lt;NUMBER&gt;3&lt;/NUMBER&gt;&lt;YEAR&gt;1997&lt;/YEAR&gt;&lt;DATE&gt;Mar&lt;/DATE&gt;&lt;TITLE&gt;Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer&lt;/TITLE&gt;&lt;PAGES&gt;496-504&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Department of Health Research and Policy, Stanford University School of Medicine, CA 94305-5092, USA.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Whittemore, A. S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Gong, G.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Itnyre, J.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Am J Hum Genet&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged, 80 and over&lt;/KEYWORD&gt;&lt;KEYWORD&gt;BRCA1 Protein/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Case-Control Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Gene Frequency&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Germ-Line Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Models, Genetic&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/epidemiology/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Pedigree&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Prevalence&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Registries&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;United States/epidemiology&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=9042908&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Struewing&lt;/Author&gt;&lt;Year&gt;1997&lt;/Year&gt;&lt;RecNum&gt;217&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Struewing, J. P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hartge, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wacholder, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Baker, S. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Berlin, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;McAdams, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Timmerman, M. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Brody, L. C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tucker, M. A.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;1997&lt;/YEAR&gt;&lt;TITLE&gt;The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews&lt;/TITLE&gt;&lt;SECONDARY_TITLE&gt;New England Journal of Medicine&lt;/SECONDARY_TITLE&gt;&lt;VOLUME&gt;336&lt;/VOLUME&gt;&lt;NUMBER&gt;20&lt;/NUMBER&gt;&lt;PAGES&gt;1401-1408&lt;/PAGES&gt;&lt;LABEL&gt;Ashkenazi Jewish&lt;/LABEL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="2" w:name="__Fieldmark__5_563349056"/><w:r><w:rPr></w:rPr><w:t>[5-7]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="2"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">, but among several ethnic groups the prevalence is considerably higher.   Notably, the frequency in those of Ashkenazi Jewish ancestry is one in 50 </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Struewing&lt;/Author&gt;&lt;Year&gt;1997&lt;/Year&gt;&lt;RecNum&gt;217&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Struewing, J. P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hartge, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wacholder, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Baker, S. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Berlin, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;McAdams, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Timmerman, M. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Brody, L. C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tucker, M. A.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;1997&lt;/YEAR&gt;&lt;TITLE&gt;The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews&lt;/TITLE&gt;&lt;SECONDARY_TITLE&gt;New England Journal of Medicine&lt;/SECONDARY_TITLE&gt;&lt;VOLUME&gt;336&lt;/VOLUME&gt;&lt;NUMBER&gt;20&lt;/NUMBER&gt;&lt;PAGES&gt;1401-1408&lt;/PAGES&gt;&lt;LABEL&gt;Ashkenazi Jewish&lt;/LABEL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Oddoux&lt;/Author&gt;&lt;Year&gt;1996&lt;/Year&gt;&lt;RecNum&gt;196&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Oddoux, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Struewing, J. P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Clayton, C. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Neuhausen, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Brody, L. C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kaback, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Haas, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Norton, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Borgen, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Jhanwar, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Goldgar, D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ostrer, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Offit, K.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;1996&lt;/YEAR&gt;&lt;TITLE&gt;The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%&lt;/TITLE&gt;&lt;SECONDARY_TITLE&gt;Nature Genetics&lt;/SECONDARY_TITLE&gt;&lt;VOLUME&gt;14&lt;/VOLUME&gt;&lt;PAGES&gt;188-190&lt;/PAGES&gt;&lt;LABEL&gt;Ashkenazi Jewish&lt;/LABEL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="3" w:name="__Fieldmark__6_563349056"/><w:r><w:rPr></w:rPr><w:t>[7, 8]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="3"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  Other groups with high frequencies of mutations include women from Iceland </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Thorlacius&lt;/Author&gt;&lt;Year&gt;1998&lt;/Year&gt;&lt;RecNum&gt;724&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;9802270&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;352&lt;/VOLUME&gt;&lt;NUMBER&gt;9137&lt;/NUMBER&gt;&lt;YEAR&gt;1998&lt;/YEAR&gt;&lt;DATE&gt;Oct 24&lt;/DATE&gt;&lt;TITLE&gt;Population-based study of risk of breast cancer in carriers of BRCA2 mutation&lt;/TITLE&gt;&lt;PAGES&gt;1337-9&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Molecular and Cell Biology Research Laboratory, Icelandic Cancer Society, Reykjavik.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Thorlacius, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Struewing, J. P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hartge, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olafsdottir, G. H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Sigvaldason, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tryggvadottir, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wacholder, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tulinius, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Eyfjord, J. E.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Lancet&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;BRCA2 Protein&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms, Male/epidemiology/genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Comparative Study&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Iceland/epidemiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Male&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasm Proteins/*genetics/isolation &amp;amp; purification&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Pedigree&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Population Surveillance/*methods&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Prostatic Neoplasms/genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Registries&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Transcription Factors/*genetics/isolation &amp;amp; purification&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=9802270&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="4" w:name="__Fieldmark__7_563349056"/><w:r><w:rPr></w:rPr><w:t>[9]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="4"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> and Poland </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Gorski&lt;/Author&gt;&lt;Year&gt;2004&lt;/Year&gt;&lt;RecNum&gt;652&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;15146557&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;110&lt;/VOLUME&gt;&lt;NUMBER&gt;5&lt;/NUMBER&gt;&lt;YEAR&gt;2004&lt;/YEAR&gt;&lt;DATE&gt;Jul 10&lt;/DATE&gt;&lt;TITLE&gt;A high proportion of founder BRCA1 mutations in Polish breast cancer families&lt;/TITLE&gt;&lt;PAGES&gt;683-6&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland. gorskib@sci.pam.szczecin.pl&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Gorski, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Jakubowska, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Huzarski, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Byrski, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Gronwald, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Grzybowska, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Mackiewicz, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Stawicka, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Bebenek, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Sorokin, D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Fiszer-Maliszewska, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Haus, O.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Janiszewska, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Niepsuj, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Gozdz, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Zaremba, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Posmyk, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Pluzanska, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kilar, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Czudowska, D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wasko, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Miturski, R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kowalczyk, J. R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Urbanski, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Szwiec, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Koc, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Debniak, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Rozmiarek, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Debniak, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Cybulski, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kowalska, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Toloczko-Grabarek, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Zajaczek, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Menkiszak, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Medrek, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Masojc, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Mierzejewski, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lubinski, J.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Int J Cancer&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Family Health&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Founder Effect&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Poland&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15146557&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="5" w:name="__Fieldmark__8_563349056"/><w:r><w:rPr></w:rPr><w:t>[10]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="5"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.    These high prevalence rates are due to the presence of founder mutations (founder mutations are one or more specific mutations in a population which have been inherited from a common ancestor, and which have become amplified through chance effects, often aided by geographical isolation of the population). </w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:i/><w:u w:val="single"/></w:rPr></w:pPr><w:r><w:rPr><w:i/><w:u w:val="single"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:b/><w:u w:val="single"/></w:rPr></w:pPr><w:r><w:rPr><w:b/><w:u w:val="single"/></w:rPr><w:t>Cancer Prevention Options</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:ind w:left="0" w:right="0" w:firstLine="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>Women with a BRCA1 or BRCA2 mutation may consider several options for breast cancer prevention.   The three main options are prophylactic mastectomy, prophylactic oophorectomy, and chemoprevention (tamoxifen or raloxifene).  In addition, a woman may elect to undergo screening (secondary prevention).  However, the goal of screening is to detect cancers at an early treatable stage, not to prevent cancer.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:i/></w:rPr></w:pPr><w:r><w:rPr><w:i/></w:rPr><w:tab/></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:i/></w:rPr></w:pPr><w:r><w:rPr><w:i/></w:rPr><w:t>Prophylactic Mastectomy</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:ind w:left="0" w:right="0" w:firstLine="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t xml:space="preserve">A prophylactic mastectomy involves the removal of both breasts in the absence of disease.  The goal of prophylactic mastectomy is to prevent breast cancer, thereby eliminating the potential for metastatic spread and death from breast cancer.   The effectiveness of prophylactic mastectomy in preventing breast cancer has been established in a small prospective study, and in historical cohort studies of primary and contralateral breast cancers.  Meijers-Heijboer and colleagues observed no cases of breast cancer after three years among 76 women who underwent prophylactic mastectomy </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Meijers-Heijboer&lt;/Author&gt;&lt;Year&gt;2001&lt;/Year&gt;&lt;RecNum&gt;394&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Meijers-Heijboer, M&lt;/AUTHOR&gt;&lt;AUTHOR&gt;VanGeel, B&lt;/AUTHOR&gt;&lt;AUTHOR&gt;VanPutten, WLJ&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Henzen-Logmans, SC&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Seynaeve, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Menke-Pluymers, MBE&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Bartels, CCM&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Verhoog, LC&lt;/AUTHOR&gt;&lt;AUTHOR&gt;VanDenOuweland, AMW&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Niermeijer, MF&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Brekelmans, TM&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Klijn, JGM&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;2001&lt;/YEAR&gt;&lt;TITLE&gt;Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation&lt;/TITLE&gt;&lt;SECONDARY_TITLE&gt;The New England Journal of Medicine&lt;/SECONDARY_TITLE&gt;&lt;VOLUME&gt;345&lt;/VOLUME&gt;&lt;NUMBER&gt;3&lt;/NUMBER&gt;&lt;PAGES&gt;158-164&lt;/PAGES&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="6" w:name="__Fieldmark__9_563349056"/><w:r><w:rPr></w:rPr><w:t>[11]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="6"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  Rebbeck and colleagues observed two cases of breast cancer in 191 women after mastectomy, compared to 184 of 378 women who retained their breasts </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Rebbeck&lt;/Author&gt;&lt;Year&gt;2004&lt;/Year&gt;&lt;RecNum&gt;658&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;14981104&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;22&lt;/VOLUME&gt;&lt;NUMBER&gt;6&lt;/NUMBER&gt;&lt;YEAR&gt;2004&lt;/YEAR&gt;&lt;DATE&gt;Mar 15&lt;/DATE&gt;&lt;TITLE&gt;Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group&lt;/TITLE&gt;&lt;PAGES&gt;1055-62&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania, Philadelphia, PA 19104-6021, USA.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Rebbeck, T. R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Friebel, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch, H. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Neuhausen, S. L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;van &amp;apos;t Veer, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Garber, J. E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Evans, G. R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Isaacs, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Matloff, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Daly, M. B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olopade, O. I.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Weber, B. L.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;J Clin Oncol&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Case-Control Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Europe/epidemiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genetic Predisposition to Disease&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Mastectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;North America/epidemiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Proportional Hazards Models&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Prospective Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, U.S. Gov&amp;apos;t, Non-P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Retrospective Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Assessment&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Treatment Outcome&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=14981104&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="7" w:name="__Fieldmark__10_563349056"/><w:r><w:rPr></w:rPr><w:t>[12]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="7"/><w:r><w:rPr></w:rPr><w:t>.</w:t></w:r><w:r><w:rPr><w:vertAlign w:val="superscript"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Metcalfe and colleagues studied contralateral breast cancer in 491 women treated for hereditary breast cancer </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Metcalfe&lt;/Author&gt;&lt;Year&gt;2004&lt;/Year&gt;&lt;RecNum&gt;655&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;15197194&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;22&lt;/VOLUME&gt;&lt;NUMBER&gt;12&lt;/NUMBER&gt;&lt;YEAR&gt;2004&lt;/YEAR&gt;&lt;DATE&gt;Jun 15&lt;/DATE&gt;&lt;TITLE&gt;Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers&lt;/TITLE&gt;&lt;PAGES&gt;2328-35&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Centre for Research on Women&amp;apos; s Health, Women&amp;apos;s College Hospital, Toronto, Ontario, Canada.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Metcalfe, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch, H. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ghadirian, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tung, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olivotto, I.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Warner, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olopade, O. I.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Eisen, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Weber, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;McLennan, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Sun, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Foulkes, W. D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;J Clin Oncol&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Age of Onset&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*genetics/*pathology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Predisposition to Disease&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasms, Second Primary/*epidemiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovariectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Prospective Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Tamoxifen/therapeutic use&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15197194&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="8" w:name="__Fieldmark__11_563349056"/><w:r><w:rPr></w:rPr><w:t>[2]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="8"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  Only one contralateral breast cancer was observed among 146 women who had undergone a contralateral mastectomy, versus 33 expected (P &lt; 0.0001).   These studies suggest that the residual breast cancer risk following mastectomy approaches zero.  Currently, total mastectomy is generally recommended over subcutaneous, or nipple-sparing mastectomy, but there are few data about failures of subcutaneous mastectomy and these reports are based on old literature </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Metcalfe&lt;/Author&gt;&lt;Year&gt;2005&lt;/Year&gt;&lt;RecNum&gt;686&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;15925821&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;6&lt;/VOLUME&gt;&lt;NUMBER&gt;6&lt;/NUMBER&gt;&lt;YEAR&gt;2005&lt;/YEAR&gt;&lt;DATE&gt;Jun&lt;/DATE&gt;&lt;TITLE&gt;Time to reconsider subcutaneous mastectomy for breast-cancer prevention?&lt;/TITLE&gt;&lt;PAGES&gt;431-4&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Faculty of Nursing, University of Toronto, Ontario, Canada.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Metcalfe, K. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Semple, J. L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Lancet Oncol&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Breast Neoplasms/*prevention &amp;amp; control/*surgery&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammaplasty/*methods&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mastectomy/*methods&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15925821&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="9" w:name="__Fieldmark__12_563349056"/><w:r><w:rPr></w:rPr><w:t>[13]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="9"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">. Technical advances in skin-sparing techniques and the availability of  approaches such as muscle-containing flaps or implantable prostheses have broadened the surgical options available to women </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Levine&lt;/Author&gt;&lt;Year&gt;2003&lt;/Year&gt;&lt;RecNum&gt;725&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;12886864&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;17&lt;/VOLUME&gt;&lt;NUMBER&gt;7&lt;/NUMBER&gt;&lt;YEAR&gt;2003&lt;/YEAR&gt;&lt;DATE&gt;Jul&lt;/DATE&gt;&lt;TITLE&gt;Prophylactic surgery in hereditary breast/ovarian cancer syndrome&lt;/TITLE&gt;&lt;PAGES&gt;932-41; discussion 946-8, 950-2&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Gynecology and Breast Services, Department of Surgery, Memorial Sloan-Kettering, Cancer Center, New York, New York, USA.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Levine, D. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Gemignani, M. L.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Oncology (Williston Park)&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Breast Neoplasms/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Clinical Trials&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Mastectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplastic Syndromes, Hereditary/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Ovariectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Tamoxifen/adverse effects/therapeutic use&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12886864&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="10" w:name="__Fieldmark__13_563349056"/><w:r><w:rPr></w:rPr><w:t>[14]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="10"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">. </w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:i/></w:rPr></w:pPr><w:r><w:rPr><w:i/></w:rPr></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:i/></w:rPr></w:pPr><w:r><w:rPr><w:i/></w:rPr><w:t>Prophylactic Oophorectomy</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:ind w:left="0" w:right="0" w:firstLine="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t xml:space="preserve">To date, most of the established cofactors for </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve">- associated breast cancers are hormonally-associated </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Narod&lt;/Author&gt;&lt;Year&gt;2002&lt;/Year&gt;&lt;RecNum&gt;726&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;12635174&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;2&lt;/VOLUME&gt;&lt;NUMBER&gt;2&lt;/NUMBER&gt;&lt;YEAR&gt;2002&lt;/YEAR&gt;&lt;DATE&gt;Feb&lt;/DATE&gt;&lt;TITLE&gt;Modifiers of risk of hereditary breast and ovarian cancer&lt;/TITLE&gt;&lt;PAGES&gt;113-23&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Centre for Research on Women&amp;apos;s Health, Women&amp;apos;s College Hospital, 790 Bay Street, Room 750, University of Toronto, Toronto, Canada M5G 1N8. steven.narod@swchsc.on.ca&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Nat Rev Cancer&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Alleles&lt;/KEYWORD&gt;&lt;KEYWORD&gt;BRCA1 Protein/genetics/metabolism&lt;/KEYWORD&gt;&lt;KEYWORD&gt;BRCA2 Protein/genetics/metabolism&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/*etiology/*genetics/prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genetic Predisposition to Disease&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/epidemiology/*etiology/*genetics/prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Penetrance&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12635174&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="11" w:name="__Fieldmark__14_563349056"/><w:r><w:rPr></w:rPr><w:t>[15]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="11"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  The purpose of an anti-hormonal therapy is to eliminate, or to block the effect of ovarian estrogen, and probably progesterone, or to prevent aromatization of androgen to estrogen.   Anti-hormonal approaches include tamoxifen, raloxifene and other SERM’s, ovarian ablation (oophorectomy, radiation or chemical ablation) and aromatase inhibition.  Of these, only tamoxifen and oophorectomy have been well studied in women with </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> or </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA2</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> mutations. </w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:ind w:left="0" w:right="0" w:firstLine="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t xml:space="preserve">The rationale for the anti-hormonal approach comes from the observation that oophorectomy prevents breast cancer in </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> and </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA2</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> carriers.  Cohort studies estimate the reduction in hereditary breast cancer risk associated with a pre-menopausal oophorectomy to be about 50% </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Kauff&lt;/Author&gt;&lt;Year&gt;2002&lt;/Year&gt;&lt;RecNum&gt;610&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;12023992&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;346&lt;/VOLUME&gt;&lt;NUMBER&gt;21&lt;/NUMBER&gt;&lt;YEAR&gt;2002&lt;/YEAR&gt;&lt;DATE&gt;May 23&lt;/DATE&gt;&lt;TITLE&gt;Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation&lt;/TITLE&gt;&lt;PAGES&gt;1609-15&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Kauff, N. D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Satagopan, J. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Robson, M. E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Scheuer, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hensley, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hudis, C. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ellis, N. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Boyd, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Borgen, P. I.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Barakat, R. R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Norton, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Castiel, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Nafa, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Offit, K.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;N Engl J Med&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Actuarial Analysis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Comparative Study&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Disease-Free Survival&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Fallopian Tube Neoplasms/epidemiology/prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Fallopian Tubes/*surgery&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Follow-Up Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Germ-Line Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Incidence&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Age&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/epidemiology/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Ovariectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Peritoneal Neoplasms/epidemiology/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Proportional Hazards Models&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, Non-P.H.S.&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12023992&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Rebbeck&lt;/Author&gt;&lt;Year&gt;1999&lt;/Year&gt;&lt;RecNum&gt;462&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Rebbeck, T. R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Levin, A. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Eisen, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Snyder, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Watson, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Cannon-Albright, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Isaacs, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olopade, O.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Garber, J. E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Godwin, A. K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Daly, M. B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Neuhausen, S. L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch, H. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Weber, B. L.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;TITLE&gt;Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers&lt;/TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Age Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*genetics/prevention &amp;amp; control/*surgery&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Case-Control Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Estrogen Replacement Therapy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA1/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Odds Ratio&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Ovariectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Questionnaires&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Registries&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, Non-P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Time Factors&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;AUTHOR_ADDRESS&gt;T. R. Rebbeck, A. Eisen, B. L. Weber, Department of Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. trebbeck@cceb.med.upenn.edu&lt;/AUTHOR_ADDRESS&gt;&lt;ACCESSION_NUMBER&gt;10469748&lt;/ACCESSION_NUMBER&gt;&lt;SECONDARY_TITLE&gt;J Natl Cancer Inst&lt;/SECONDARY_TITLE&gt;&lt;YEAR&gt;1999&lt;/YEAR&gt;&lt;VOLUME&gt;91&lt;/VOLUME&gt;&lt;NUMBER&gt;17&lt;/NUMBER&gt;&lt;PAGES&gt;1475-9.&lt;/PAGES&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&amp;amp;form=6&amp;amp;dopt=r&amp;amp;uid=10469748&amp;#xD;http://jnci.oupjournals.org/cgi/content/full/91/17/1475&amp;#xD;http://jnci.oupjournals.org/cgi/content/abstract/91/17/1475&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Rebbeck&lt;/Author&gt;&lt;Year&gt;2002&lt;/Year&gt;&lt;RecNum&gt;585&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;12023993&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;346&lt;/VOLUME&gt;&lt;NUMBER&gt;21&lt;/NUMBER&gt;&lt;YEAR&gt;2002&lt;/YEAR&gt;&lt;DATE&gt;May 23&lt;/DATE&gt;&lt;TITLE&gt;Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations&lt;/TITLE&gt;&lt;PAGES&gt;1616-22&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104-6021, USA. trebbeck@cceb.med.upenn.edu&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Rebbeck, T. R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch, H. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Neuhausen, S. L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Van&amp;apos;t Veer, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Garber, J. E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Evans, G.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Isaacs, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Daly, M. B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Matloff, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olopade, O. I.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Weber, B. L.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;N Engl J Med&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Case-Control Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Cystadenocarcinoma, Serous/epidemiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Germ-Line Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Incidence&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Age&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/epidemiology/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Ovariectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Peritoneal Neoplasms/epidemiology/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Proportional Hazards Models&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, Non-P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12023993&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="12" w:name="__Fieldmark__15_563349056"/><w:r><w:rPr></w:rPr><w:t>[16-18]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="12"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  A recent case-control study reported that the risk reduction might be even greater if the oophorectomy is performed before age 40 and that the duration of protection is approximately 15 years </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Eisen&lt;/Author&gt;&lt;Year&gt;2005&lt;/Year&gt;&lt;RecNum&gt;681&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;16234515&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;23&lt;/VOLUME&gt;&lt;NUMBER&gt;30&lt;/NUMBER&gt;&lt;YEAR&gt;2005&lt;/YEAR&gt;&lt;DATE&gt;Oct 20&lt;/DATE&gt;&lt;TITLE&gt;Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study&lt;/TITLE&gt;&lt;PAGES&gt;7491-6&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Toronto-Sunnybrook Regional Cancer Center, Toronto, ON, Canada.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Eisen, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lubinski, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Klijn, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Moller, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch, H. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Offit, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Weber, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Rebbeck, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Neuhausen, S. L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ghadirian, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Foulkes, W. D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Gershoni-Baruch, R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Friedman, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Rennert, G.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wagner, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Isaacs, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kim-Sing, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ainsworth, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Sun, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;J Clin Oncol&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Age of Onset&lt;/KEYWORD&gt;&lt;KEYWORD&gt;BRCA1 Protein/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;BRCA2 Protein/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Case-Control Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Contraceptives, Oral&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Odds Ratio&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Ovariectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, N.I.H., Extramural&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16234515&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="13" w:name="__Fieldmark__16_563349056"/><w:r><w:rPr></w:rPr><w:t>[19]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="13"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  Short-term use of estrogen in young women following oophorectomy might abrogate some of the breast cancer protection associated with oophorectomy; however, such interventions in symptomatic young women may be of benefit in improving quality of life.  In one study the effectiveness of prophylactic oophorectomy was not reduced by the addition of hormone replacement therapy </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Rebbeck&lt;/Author&gt;&lt;Year&gt;2002&lt;/Year&gt;&lt;RecNum&gt;585&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;12023993&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;346&lt;/VOLUME&gt;&lt;NUMBER&gt;21&lt;/NUMBER&gt;&lt;YEAR&gt;2002&lt;/YEAR&gt;&lt;DATE&gt;May 23&lt;/DATE&gt;&lt;TITLE&gt;Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations&lt;/TITLE&gt;&lt;PAGES&gt;1616-22&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104-6021, USA. trebbeck@cceb.med.upenn.edu&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Rebbeck, T. R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch, H. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Neuhausen, S. L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Van&amp;apos;t Veer, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Garber, J. E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Evans, G.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Isaacs, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Daly, M. B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Matloff, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olopade, O. I.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Weber, B. L.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;N Engl J Med&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Case-Control Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Cystadenocarcinoma, Serous/epidemiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Germ-Line Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Incidence&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Age&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/epidemiology/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Ovariectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Peritoneal Neoplasms/epidemiology/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Proportional Hazards Models&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, Non-P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12023993&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="14" w:name="__Fieldmark__17_563349056"/><w:r><w:rPr></w:rPr><w:t>[18]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="14"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  There are no comparable data on the degree of protection against breast cancer offered by other forms of ovarian ablation such as radiation or GNRH agonists.   A GNRH agonist may be preferred by a woman who wishes to preserve her fertility, but the use of these drugs in </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> carriers is not widespread and their effectiveness in reducing breast cancer risk is unknown.  There remains the concern that these non-surgical approaches to ovarian ablation do not address risk for ovarian of fallopian tube cancers. </w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:i/></w:rPr></w:pPr><w:r><w:rPr><w:i/></w:rPr></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:i/></w:rPr></w:pPr><w:r><w:rPr><w:i/></w:rPr><w:t>Tamoxifen</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:ind w:left="0" w:right="0" w:firstLine="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t xml:space="preserve">Tamoxifen is a selective estrogen receptor modulator (SERM) that competes with estrogen for binding to the estrogen receptor.  In humans, tamoxifen acts as an estrogen antagonist in breast tissue, inhibiting the growth of estrogen-dependent breast tumors </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Pritchard&lt;/Author&gt;&lt;Year&gt;2001&lt;/Year&gt;&lt;RecNum&gt;502&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&amp;amp;form=6&amp;amp;dopt=r&amp;amp;uid=11795385&lt;/URL&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Pritchard, K. I.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;TITLE&gt;Breast cancer prevention with selective estrogen receptor modulators: a perspective&lt;/TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Breast Neoplasms/drug therapy/epidemiology/pathology/*prevention &amp;amp;&lt;/KEYWORD&gt;&lt;KEYWORD&gt;control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Incidence&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Meta-Analysis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasm Invasiveness&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Receptors, Estrogen/drug effects/physiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Selective Estrogen Receptor Modulators/*therapeutic use&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Tamoxifen/*therapeutic use&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;AUTHOR_ADDRESS&gt;Division of Clinical Trials and Epidemiology, Toronto-Sunnybrook Regional Cancer Centre, Ontario, Canada. kathy.pritchard@tsrcc.on.ca&lt;/AUTHOR_ADDRESS&gt;&lt;ACCESSION_NUMBER&gt;11795385&lt;/ACCESSION_NUMBER&gt;&lt;SECONDARY_TITLE&gt;Ann N Y Acad Sci&lt;/SECONDARY_TITLE&gt;&lt;YEAR&gt;2001&lt;/YEAR&gt;&lt;VOLUME&gt;949&lt;/VOLUME&gt;&lt;PAGES&gt;89-98.&lt;/PAGES&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="15" w:name="__Fieldmark__18_563349056"/><w:r><w:rPr></w:rPr><w:t>[20]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="15"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  On theoretical grounds, tamoxifen should not reduce the incidence of estrogen-receptor negative breast cancers – and most breast cancers which occur in </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t xml:space="preserve">BRCA1 </w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> (but not </w:t></w:r><w:r><w:rPr><w:i/><w:iCs/></w:rPr><w:t>BRCA2</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve">) carriers are estrogen-receptor negative. An attempt to address this issue was made in the NSABP P1 trial; however only eight </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> carriers with breast cancer were identified in the follow-up period </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;King&lt;/Author&gt;&lt;Year&gt;2001&lt;/Year&gt;&lt;RecNum&gt;487&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&amp;amp;form=6&amp;amp;dopt=r&amp;amp;uid=11710890&lt;/URL&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;King, M. C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wieand, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hale, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lee, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Walsh, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Owens, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tait, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ford, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Dunn, B. K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Costantino, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wickerham, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wolmark, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Fisher, B.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;TITLE&gt;Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial&lt;/TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Antineoplastic Agents, Hormonal/*therapeutic use&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/*genetics/metabolism/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;DNA Mutational Analysis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Double-Blind Method&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Predisposition to Disease&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Incidence&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Age&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Receptors, Estrogen&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Tamoxifen/*therapeutic use&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;AUTHOR_ADDRESS&gt;University of Washington, Seattle, WA 98195, USA. mcking@u.washington.edu&lt;/AUTHOR_ADDRESS&gt;&lt;ACCESSION_NUMBER&gt;11710890&lt;/ACCESSION_NUMBER&gt;&lt;SECONDARY_TITLE&gt;Jama&lt;/SECONDARY_TITLE&gt;&lt;YEAR&gt;2001&lt;/YEAR&gt;&lt;VOLUME&gt;286&lt;/VOLUME&gt;&lt;NUMBER&gt;18&lt;/NUMBER&gt;&lt;PAGES&gt;2251-6.&lt;/PAGES&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="16" w:name="__Fieldmark__19_563349056"/><w:r><w:rPr></w:rPr><w:t>[21]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="16"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  No protective effect was seen with tamoxifen for BRCA1 carriers, but the number of cases is too small for the study to be definitive.  In a large case-control study tamoxifen was found to reduce the incidence of contralateral breast cancer in affected </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> and </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA2</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> carriers by about one-half (OR = 0.5; 95% CI 0.30-0.85)</w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Gronwald&lt;/Author&gt;&lt;Year&gt;2006&lt;/Year&gt;&lt;RecNum&gt;744&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;16331614&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;118&lt;/VOLUME&gt;&lt;NUMBER&gt;9&lt;/NUMBER&gt;&lt;YEAR&gt;2006&lt;/YEAR&gt;&lt;DATE&gt;May 1&lt;/DATE&gt;&lt;TITLE&gt;Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update&lt;/TITLE&gt;&lt;PAGES&gt;2281-4&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical Academy, Szczecin, Poland.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Gronwald, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tung, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Foulkes, W. D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Offit, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Gershoni, R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Daly, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kim-Sing, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olsson, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ainsworth, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Eisen, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Saal, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Friedman, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olopade, O.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Osborne, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Weitzel, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ghadirian, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lubinski, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Sun, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Int J Cancer&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Antineoplastic Agents, Hormonal/*therapeutic use&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/etiology/*genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Case-Control Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;DNA Mutational Analysis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genetic Predisposition to Disease&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Laterality&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasms, Second Primary/etiology/genetics/prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Odds Ratio&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Pedigree&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Premenopause&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, N.I.H., Extramural&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, U.S. Gov&amp;apos;t, Non-P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Retrospective Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Assessment&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Tamoxifen/*therapeutic use&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16331614&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="17" w:name="__Fieldmark__20_563349056"/><w:r><w:rPr></w:rPr><w:t>[22]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="17"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  To the extent that contralateral cancers in carriers are representative of all new primary breast cancers, the results of this study might be extrapolated to the prevention of first primary breast cancers. But this conclusion would be invalid if the two primary cancers were not independent; for example if tamoxifen were given only to ER-positive patients, and if the ER status of bilateral cancers were highly correlated.  In a recent study by Weitzel et al, the majority of contralateral breast cancers following ER-positive breast cancer were in fact, ER-negative, suggesting that tamoxifen prevents ER-negative contralateral breast cancers </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Weitzel&lt;/Author&gt;&lt;Year&gt;2005&lt;/Year&gt;&lt;RecNum&gt;727&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;15941968&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;14&lt;/VOLUME&gt;&lt;NUMBER&gt;6&lt;/NUMBER&gt;&lt;YEAR&gt;2005&lt;/YEAR&gt;&lt;DATE&gt;Jun&lt;/DATE&gt;&lt;TITLE&gt;A comparison of bilateral breast cancers in BRCA carriers&lt;/TITLE&gt;&lt;PAGES&gt;1534-8&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;The Centre for Research in Women&amp;apos;s Health, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8. steven.narod@sw.ca.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Weitzel, J. N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Robson, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Pasini, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Manoukian, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Stoppa-Lyonnet, D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch, H. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;McLennan, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Foulkes, W. D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wagner, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tung, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ghadirian, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olopade, O.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Isaacs, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kim-Sing, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Moller, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Neuhausen, S. L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Metcalfe, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Sun, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Cancer Epidemiol Biomarkers Prev&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Age of Onset&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*genetics/pathology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Comparative Study&lt;/KEYWORD&gt;&lt;KEYWORD&gt;DNA Mutational Analysis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasm Staging&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasms, Second Primary/*genetics/pathology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Receptors, Estrogen/*analysis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, N.I.H., Extramural&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15941968&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="18" w:name="__Fieldmark__21_563349056"/><w:r><w:rPr></w:rPr><w:t>[23]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="18"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">. </w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:ind w:left="0" w:right="0" w:firstLine="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>Recent research with the drug raloxifene has demonstrated that this drug reduces the risk of developing breast cancer in post-menopausal women (NSABP).  However, it has not been tested in women with a BRCA1 or BRCA2 mutation.  This form of chemoprevention may become an option for post-menopausal women with a BRCA1 or BRCA2 mutation.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:i/></w:rPr></w:pPr><w:r><w:rPr><w:i/></w:rPr></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:i/></w:rPr></w:pPr><w:r><w:rPr><w:i/></w:rPr><w:t>Screening</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:ind w:left="0" w:right="0" w:firstLine="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t xml:space="preserve">The goal of screening is to identify a breast cancer at a stage when surgical cure is likely.  Traditionally, this includes small breast cancers (&lt;1 cm) that are node-negative and with no evidence of distant spread.  Cure can be expected for the great majority of these cases.  But </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve">-associated breast cancers are typically of high grade and are estrogen-receptor negative and so prognosis might be expected to be worse than average.  Among </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> carriers there was little correlation between tumor size and lymph-node positivity in one study; about one-third of </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> carriers had lymph node metastases detected at diagnosis, regardless of tumor size </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Foulkes&lt;/Author&gt;&lt;Year&gt;2003&lt;/Year&gt;&lt;RecNum&gt;605&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Foulkes, W. D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Metcalfe, K. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hanna, W.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ghadirian, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tung, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olopade, O.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Weber, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;McLennan, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Olivotto, I.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Sun, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Chappuis, P. O.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Begin, L. R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Brunet, J. S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;2003&lt;/YEAR&gt;&lt;TITLE&gt;Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma&lt;/TITLE&gt;&lt;SECONDARY_TITLE&gt;Cancer&lt;/SECONDARY_TITLE&gt;&lt;VOLUME&gt;98&lt;/VOLUME&gt;&lt;NUMBER&gt;8&lt;/NUMBER&gt;&lt;PAGES&gt;1569-1577&lt;/PAGES&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="19" w:name="__Fieldmark__22_563349056"/><w:r><w:rPr></w:rPr><w:t>[24]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="19"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  Therefore it may be problematic to predict the benefits of screening using survival data generated from a comparison group of non-carriers.  </w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:tab/><w:t xml:space="preserve">A number of advisory groups in the U.S. and Europe have published recommendations for surveillance for women at hereditary risk for breast cancer and ovarian cancer </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Burke&lt;/Author&gt;&lt;Year&gt;1997&lt;/Year&gt;&lt;RecNum&gt;24&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;LABEL&gt;24&lt;/LABEL&gt;&lt;YEAR&gt;1997&lt;/YEAR&gt;&lt;TITLE&gt;Recommendations for follow-up care of individuals with an inherited predisposition to cancer&lt;/TITLE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Burke,W.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Daly,M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Garber,J.E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Botkin,J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ellis-Kahn,M.J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lynch,P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;McTiernan,A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Offit,K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Perlman,J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Petersen,G.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Thomson,E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Varricchio,C.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;JAMA&lt;/SECONDARY_TITLE&gt;&lt;PAGES&gt;997-1003&lt;/PAGES&gt;&lt;VOLUME&gt;277&lt;/VOLUME&gt;&lt;NUMBER&gt;12&lt;/NUMBER&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Eisinger&lt;/Author&gt;&lt;Year&gt;1998&lt;/Year&gt;&lt;RecNum&gt;728&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;9818066&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;9&lt;/VOLUME&gt;&lt;NUMBER&gt;9&lt;/NUMBER&gt;&lt;YEAR&gt;1998&lt;/YEAR&gt;&lt;DATE&gt;Sep&lt;/DATE&gt;&lt;TITLE&gt;Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee&lt;/TITLE&gt;&lt;PAGES&gt;939-50&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;INSERM CRI 9703, Paoli-Calmettes Institute, Marseille, France.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Eisinger, F.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Alby, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Bremond, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Dauplat, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Espie, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Janiaud, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kuttenn, F.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lebrun, J. P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Lefranc, J. P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Pierret, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Sobol, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Stoppa-Lyonnet, D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Thouvenin, D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tristant, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Feingold, J.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Ann Oncol&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Breast Neoplasms/epidemiology/genetics/*prevention &amp;amp; control/therapy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Delivery of Health Care/standards&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;France&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Counseling/legislation &amp;amp; jurisprudence&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/epidemiology/genetics/*prevention &amp;amp; control/therapy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Primary Prevention/standards&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=9818066&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Pichert&lt;/Author&gt;&lt;Year&gt;2003&lt;/Year&gt;&lt;RecNum&gt;729&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;12488287&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;14&lt;/VOLUME&gt;&lt;NUMBER&gt;1&lt;/NUMBER&gt;&lt;YEAR&gt;2003&lt;/YEAR&gt;&lt;DATE&gt;Jan&lt;/DATE&gt;&lt;TITLE&gt;Evidence-based management options for women at increased breast/ovarian cancer risk&lt;/TITLE&gt;&lt;PAGES&gt;9-19&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Division of Oncology, Department of Medicine, University Hospital, Zurich, Switzerland. gpichert@bluewin.ch&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Pichert, G.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Bolliger, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Buser, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Pagani, O.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Ann Oncol&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Breast Neoplasms/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Evidence-Based Medicine&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA1/physiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA2/physiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/genetics/*prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Risk Reduction Behavior&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12488287&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="20" w:name="__Fieldmark__23_563349056"/><w:r><w:rPr></w:rPr><w:t>[25-27]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="20"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  In general, these guidelines called for annual mammography beginning around age 25, as well as monthly breast self-examinations (BSE) and </w:t></w:r><w:r><w:rPr><w:iCs/></w:rPr><w:t xml:space="preserve">clinical breast examination (CBE) once to twice a year. </w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:ind w:left="0" w:right="0" w:firstLine="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve">-associated tumors may be particularly hard to detect mammographically. Pushing margins, breast density, and mutation status contribute independently to false-negative mammograms in </w:t></w:r><w:r><w:rPr><w:i/><w:iCs/></w:rPr><w:t xml:space="preserve">BRCA </w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve">heterozygotes </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Tilanus-Linthorst&lt;/Author&gt;&lt;Year&gt;2002&lt;/Year&gt;&lt;RecNum&gt;734&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;12353239&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;102&lt;/VOLUME&gt;&lt;NUMBER&gt;1&lt;/NUMBER&gt;&lt;YEAR&gt;2002&lt;/YEAR&gt;&lt;DATE&gt;Nov 1&lt;/DATE&gt;&lt;TITLE&gt;A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography&lt;/TITLE&gt;&lt;PAGES&gt;91-5&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Department of Surgery, Erasmus University Medical Center Rotterdam, The Netherlands. tilanus@chih.azr.nl&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Tilanus-Linthorst, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Verhoog, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Obdeijn, I. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Bartels, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Menke-Pluymers, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Eggermont, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Klijn, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Meijers-Heijboer, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;van der Kwast, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Brekelmans, C.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Int J Cancer&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Age of Onset&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast/cytology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/pathology/*radiography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Carcinoma, Intraductal, Noninfiltrating/pathology/*radiography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Case-Control Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Comparative Study&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Cross-Sectional Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;False Negative Reactions&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Germ-Line Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Magnetic Resonance Imaging&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Mammography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasm Invasiveness/pathology/*radiography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Physical Examination&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12353239&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="21" w:name="__Fieldmark__24_563349056"/><w:r><w:rPr></w:rPr><w:t>[28]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="21"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  U.S and U.K studies of women under 50 with a family history of breast cancer reported  sensitivities of 63-70% </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Kerlikowske&lt;/Author&gt;&lt;Year&gt;2000&lt;/Year&gt;&lt;RecNum&gt;735&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;11103055&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;133&lt;/VOLUME&gt;&lt;NUMBER&gt;11&lt;/NUMBER&gt;&lt;YEAR&gt;2000&lt;/YEAR&gt;&lt;DATE&gt;Dec 5&lt;/DATE&gt;&lt;TITLE&gt;Performance of screening mammography among women with and without a first-degree relative with breast cancer&lt;/TITLE&gt;&lt;PAGES&gt;855-63&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;General Internal Medicine Section, 111A1, San Francisco Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA. kerliko@itsa.ucsf.edu&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Kerlikowske, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Carney, P. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Geller, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Mandelson, M. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Taplin, S. H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Malvin, K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ernster, V.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Urban, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Cutter, G.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Rosenberg, R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ballard-Barbash, R.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Ann Intern Med&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Biopsy/statistics &amp;amp; numerical data&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/diagnosis/*epidemiology/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Carcinoma in Situ/diagnosis/epidemiology/genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Carcinoma, Ductal, Breast/diagnosis/epidemiology/genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Cross-Sectional Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Family&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Follow-Up Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammography/*statistics &amp;amp; numerical data&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mass Screening/*statistics &amp;amp; numerical data&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Predictive Value of Tests&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Registries&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, U.S. Gov&amp;apos;t, Non-P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, U.S. Gov&amp;apos;t, P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Sensitivity and Specificity&lt;/KEYWORD&gt;&lt;KEYWORD&gt;United States/epidemiology&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11103055&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="22" w:name="__Fieldmark__25_563349056"/><w:r><w:rPr></w:rPr><w:t>[29]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="22"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> and 44% </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Kollias&lt;/Author&gt;&lt;Year&gt;1998&lt;/Year&gt;&lt;RecNum&gt;736&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;9797701&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;34&lt;/VOLUME&gt;&lt;NUMBER&gt;6&lt;/NUMBER&gt;&lt;YEAR&gt;1998&lt;/YEAR&gt;&lt;DATE&gt;May&lt;/DATE&gt;&lt;TITLE&gt;Screening women aged less than 50 years with a family history of breast cancer&lt;/TITLE&gt;&lt;PAGES&gt;878-83&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Nottingham City Hospital, U.K.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Kollias, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Sibbering, D. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Blamey, R. W.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Holland, P. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Obuszko, Z.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wilson, A. R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Evans, A. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ellis, I. O.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Elston, C. W.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Eur J Cancer&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adolescent&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*diagnosis/genetics/prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Carcinoma in Situ/*diagnosis/genetics/prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Carcinoma, Ductal, Breast/*diagnosis/genetics/prevention &amp;amp; control&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Follow-Up Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammography/methods/standards&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mass Screening/*methods/standards&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Pedigree&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Prognosis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Sensitivity and Specificity&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=9797701&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="23" w:name="__Fieldmark__26_563349056"/><w:r><w:rPr></w:rPr><w:t>[30]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="23"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">, respectively.  Goffin and colleagues </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Goffin&lt;/Author&gt;&lt;Year&gt;2001&lt;/Year&gt;&lt;RecNum&gt;737&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;11717339&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;93&lt;/VOLUME&gt;&lt;NUMBER&gt;22&lt;/NUMBER&gt;&lt;YEAR&gt;2001&lt;/YEAR&gt;&lt;DATE&gt;Nov 21&lt;/DATE&gt;&lt;TITLE&gt;Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer&lt;/TITLE&gt;&lt;PAGES&gt;1754-5&lt;/PAGES&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Goffin, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Chappuis, P. O.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wong, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Foulkes, W. D.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;J Natl Cancer Inst&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*diagnosis/*genetics/pathology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genetic Predisposition to Disease&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Magnetic Resonance Imaging/standards/*statistics &amp;amp; numerical data&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammography/standards/*statistics &amp;amp; numerical data&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Practice Guidelines&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, U.S. Gov&amp;apos;t, Non-P.H.S.&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Sensitivity and Specificity&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11717339&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="24" w:name="__Fieldmark__27_563349056"/><w:r><w:rPr></w:rPr><w:t>[31]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="24"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> found that only 2 of 8 breast cancers (25%) in </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA1</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> carriers were detectable by mammogram at diagnosis, versus 27 of 35 (77%) from non-carrier controls ( p = 0.01).  In a large cohort at a single center, of 12 breast tumors diagnosed in </w:t></w:r><w:r><w:rPr><w:i/><w:iCs/></w:rPr><w:t>BRCA</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> mutation carriers, less than half were found by mammogram </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Scheuer&lt;/Author&gt;&lt;Year&gt;2002&lt;/Year&gt;&lt;RecNum&gt;501&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Scheuer, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kauff, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Robson, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kelly, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Barakat, R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Satagopan, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ellis, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hensley, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Boyd, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Borgen, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Norton, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Offit, K.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;TITLE&gt;Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers&lt;/TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/diagnosis/*genetics/*surgery&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Fallopian Tube Neoplasms/diagnosis/genetics/surgery&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Counseling&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Screening&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Age&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/diagnosis/*genetics/*surgery&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovariectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Prospective Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, Non-P.H.S.&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;AUTHOR_ADDRESS&gt;Clinical Genetics, Breast Cancer Medicine, and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New york, NY 10021, USA.&lt;/AUTHOR_ADDRESS&gt;&lt;ACCESSION_NUMBER&gt;11870168&lt;/ACCESSION_NUMBER&gt;&lt;SECONDARY_TITLE&gt;J Clin Oncol&lt;/SECONDARY_TITLE&gt;&lt;YEAR&gt;2002&lt;/YEAR&gt;&lt;VOLUME&gt;20&lt;/VOLUME&gt;&lt;NUMBER&gt;5&lt;/NUMBER&gt;&lt;PAGES&gt;1260-8.&lt;/PAGES&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&amp;amp;form=6&amp;amp;dopt=r&amp;amp;uid=11870168&amp;#xD;http://www.jco.org/cgi/content/full/20/5/1260&amp;#xD;http://www.jco.org/cgi/content/abstract/20/5/1260&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="25" w:name="__Fieldmark__28_563349056"/><w:r><w:rPr></w:rPr><w:t>[32]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="25"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.   Breast magnetic resonance imaging (MRI) offers the promise of a greatly improved sensitivity of detection of breast cancers in those at high risk.  Early studies reported sensitivities in the range of 100% for invasive breast cancer, but later studies which included DCIS reported lower sensitivities </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Brekelmans&lt;/Author&gt;&lt;Year&gt;2001&lt;/Year&gt;&lt;RecNum&gt;739&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;11181654&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;19&lt;/VOLUME&gt;&lt;NUMBER&gt;4&lt;/NUMBER&gt;&lt;YEAR&gt;2001&lt;/YEAR&gt;&lt;DATE&gt;Feb 15&lt;/DATE&gt;&lt;TITLE&gt;Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk&lt;/TITLE&gt;&lt;PAGES&gt;924-30&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Department of Medical Oncology, Family Cancer Clinic, Dr Daniel den Hoed Cancer Center, Rotterdam, the Netherlands. brekelmans@onch.azr.nl&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Brekelmans, C. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Seynaeve, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Bartels, C. C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tilanus-Linthorst, M. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Meijers-Heijboer, E. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Crepin, C. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;van Geel, A. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Menke, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Verhoog, L. C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;van den Ouweland, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Obdeijn, I. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Klijn, J. G.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;J Clin Oncol&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Age Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;BRCA2 Protein&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*diagnosis/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasm Proteins/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Transcription Factors/*genetics&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11181654&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Scheuer&lt;/Author&gt;&lt;Year&gt;2002&lt;/Year&gt;&lt;RecNum&gt;501&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Scheuer, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kauff, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Robson, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kelly, B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Barakat, R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Satagopan, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ellis, N.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hensley, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Boyd, J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Borgen, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Norton, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Offit, K.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;TITLE&gt;Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers&lt;/TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/diagnosis/*genetics/*surgery&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Fallopian Tube Neoplasms/diagnosis/genetics/surgery&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Counseling&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Screening&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Heterozygote&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Age&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovarian Neoplasms/diagnosis/*genetics/*surgery&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ovariectomy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Prospective Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Support, U.S. Gov&amp;apos;t, Non-P.H.S.&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;AUTHOR_ADDRESS&gt;Clinical Genetics, Breast Cancer Medicine, and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New york, NY 10021, USA.&lt;/AUTHOR_ADDRESS&gt;&lt;ACCESSION_NUMBER&gt;11870168&lt;/ACCESSION_NUMBER&gt;&lt;SECONDARY_TITLE&gt;J Clin Oncol&lt;/SECONDARY_TITLE&gt;&lt;YEAR&gt;2002&lt;/YEAR&gt;&lt;VOLUME&gt;20&lt;/VOLUME&gt;&lt;NUMBER&gt;5&lt;/NUMBER&gt;&lt;PAGES&gt;1260-8.&lt;/PAGES&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&amp;amp;form=6&amp;amp;dopt=r&amp;amp;uid=11870168&amp;#xD;http://www.jco.org/cgi/content/full/20/5/1260&amp;#xD;http://www.jco.org/cgi/content/abstract/20/5/1260&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Tilanus-Linthorst&lt;/Author&gt;&lt;Year&gt;2000&lt;/Year&gt;&lt;RecNum&gt;740&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;11079159&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;63&lt;/VOLUME&gt;&lt;NUMBER&gt;1&lt;/NUMBER&gt;&lt;YEAR&gt;2000&lt;/YEAR&gt;&lt;DATE&gt;Sep&lt;/DATE&gt;&lt;TITLE&gt;First experiences in screening women at high risk for breast cancer with MR imaging&lt;/TITLE&gt;&lt;PAGES&gt;53-60&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Department of Radiology, Daniel den Hoed Clinic, Erasmus University Rotterdam, The Netherlands. tilanus@radh.azr.nl&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Tilanus-Linthorst, M. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Obdeijn, I. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Bartels, K. C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;de Koning, H. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Oudkerk, M.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Breast Cancer Res Treat&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Age Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Biopsy, Needle&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/genetics/*pathology/radiography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Comparative Study&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Cost-Benefit Analysis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Predisposition to Disease&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Health Care Costs&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Magnetic Resonance Imaging/economics/methods&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Mammography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mass Screening&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Neoplasm Recurrence, Local&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Physical Examination&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Sensitivity and Specificity&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11079159&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Stoutjesdijk&lt;/Author&gt;&lt;Year&gt;2001&lt;/Year&gt;&lt;RecNum&gt;409&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Stoutjesdijk, M. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Boetes, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Jager, G. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Beex, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Bult, P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hendriks, J. H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Laheij, R. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Massuger, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;van Die, L. E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Wobbes, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Barentsz, J. O.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;TITLE&gt;Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer&lt;/TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Area Under Curve&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*diagnosis/*genetics/radiography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Diagnosis, Differential&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Human&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Magnetic Resonance Imaging&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mass Screening/*methods&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Age&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Predictive Value of Tests&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Retrospective Studies&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;AUTHOR_ADDRESS&gt;Department of Radiology, University Medical Center St Radboud, Nijmegen, The Netherlands. m.stoutjesdijk@rdiag.azn.nl&lt;/AUTHOR_ADDRESS&gt;&lt;ACCESSION_NUMBER&gt;11459871&lt;/ACCESSION_NUMBER&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&amp;amp;form=6&amp;amp;dopt=r&amp;amp;uid=11459871&amp;#xD;http://jnci.oupjournals.org/cgi/content/full/93/14/1095&amp;#xD;http://jnci.oupjournals.org/cgi/content/abstract/93/14/1095&lt;/URL&gt;&lt;SECONDARY_TITLE&gt;J Natl Cancer Inst&lt;/SECONDARY_TITLE&gt;&lt;YEAR&gt;2001&lt;/YEAR&gt;&lt;VOLUME&gt;93&lt;/VOLUME&gt;&lt;NUMBER&gt;14&lt;/NUMBER&gt;&lt;PAGES&gt;1095-102.&lt;/PAGES&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Morris&lt;/Author&gt;&lt;Year&gt;2003&lt;/Year&gt;&lt;RecNum&gt;741&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;12933450&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;181&lt;/VOLUME&gt;&lt;NUMBER&gt;3&lt;/NUMBER&gt;&lt;YEAR&gt;2003&lt;/YEAR&gt;&lt;DATE&gt;Sep&lt;/DATE&gt;&lt;TITLE&gt;MRI of occult breast carcinoma in a high-risk population&lt;/TITLE&gt;&lt;PAGES&gt;619-26&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Breast Imaging Section, Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA. morrise@mskcc.org&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Morris, E. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Liberman, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Ballon, D. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Robson, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Abramson, A. F.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Heerdt, A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Dershaw, D. D.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;AJR Am J Roentgenol&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged, 80 and over&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Biopsy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*pathology/radiography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Carcinoma, Ductal, Breast/*pathology/radiography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Carcinoma, Intraductal, Noninfiltrating/*pathology/radiography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Magnetic Resonance Imaging&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Predictive Value of Tests&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Retrospective Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Assessment&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Time Factors&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12933450&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Kriege&lt;/Author&gt;&lt;Year&gt;2004&lt;/Year&gt;&lt;RecNum&gt;684&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;15282350&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;351&lt;/VOLUME&gt;&lt;NUMBER&gt;5&lt;/NUMBER&gt;&lt;YEAR&gt;2004&lt;/YEAR&gt;&lt;DATE&gt;Jul 29&lt;/DATE&gt;&lt;TITLE&gt;Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition&lt;/TITLE&gt;&lt;PAGES&gt;427-37&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Rotterdam Family Cancer Clinic, Department of Medical Oncology, Erasmus Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Kriege, M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Brekelmans, C. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Boetes, C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Besnard, P. E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Zonderland, H. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Obdeijn, I. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Manoliu, R. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Kok, T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Peterse, H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tilanus-Linthorst, M. M.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Muller, S. H.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Meijer, S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Oosterwijk, J. C.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Beex, L. V.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Tollenaar, R. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;de Koning, H. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Rutgers, E. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Klijn, J. G.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;N Engl J Med&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*diagnosis/genetics/pathology/radiography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Case-Control Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Chi-Square Distribution&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Comparative Study&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Predisposition to Disease&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Germ-Line Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Magnetic Resonance Imaging&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Mammography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mass Screening/methods&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Prospective Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;ROC Curve&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Sensitivity and Specificity&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Survival Analysis&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15282350&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Liberman&lt;/Author&gt;&lt;Year&gt;2003&lt;/Year&gt;&lt;RecNum&gt;742&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;12872360&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;98&lt;/VOLUME&gt;&lt;NUMBER&gt;2&lt;/NUMBER&gt;&lt;YEAR&gt;2003&lt;/YEAR&gt;&lt;DATE&gt;Jul 15&lt;/DATE&gt;&lt;TITLE&gt;Probably benign lesions at breast magnetic resonance imaging: preliminary experience in high-risk women&lt;/TITLE&gt;&lt;PAGES&gt;377-88&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Breast Imaging Section, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. libermal@mskcc.org&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Liberman, L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Morris, E. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Benton, C. L.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Abramson, A. F.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Dershaw, D. D.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Cancer&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged, 80 and over&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*diagnosis&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Diagnosis, Differential&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Magnetic Resonance Imaging&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Predictive Value of Tests&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Retrospective Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12872360&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Robson&lt;/Author&gt;&lt;Year&gt;2004&lt;/Year&gt;&lt;RecNum&gt;743&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;15367560&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;292&lt;/VOLUME&gt;&lt;NUMBER&gt;11&lt;/NUMBER&gt;&lt;YEAR&gt;2004&lt;/YEAR&gt;&lt;DATE&gt;Sep 15&lt;/DATE&gt;&lt;TITLE&gt;Breast MRI for women with hereditary cancer risk&lt;/TITLE&gt;&lt;PAGES&gt;1368-70&lt;/PAGES&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Robson, M. E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Offit, K.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Jama&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*diagnosis/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Magnetic Resonance Imaging&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15367560&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="26" w:name="__Fieldmark__29_563349056"/><w:r><w:rPr></w:rPr><w:t>[32-39]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="26"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.  In the largest series reported to date, the sensitivity of MRI was 83% for invasive disease, but was only 71% overall </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Gui&lt;/Author&gt;&lt;Year&gt;2001&lt;/Year&gt;&lt;RecNum&gt;733&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;11527694&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;37&lt;/VOLUME&gt;&lt;NUMBER&gt;13&lt;/NUMBER&gt;&lt;YEAR&gt;2001&lt;/YEAR&gt;&lt;DATE&gt;Sep&lt;/DATE&gt;&lt;TITLE&gt;The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography?&lt;/TITLE&gt;&lt;PAGES&gt;1668-73&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Department of Academic Surgery, Royal Marsden NHS Trust and Institute of Cancer Research, London, UK. gerald.gui@rhm.nthames.nhs.uk&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Gui, G. P.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hogben, R. K.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Walsh, G.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;A&amp;apos;Hern, R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Eeles, R.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Eur J Cancer&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*epidemiology/genetics/radiography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Cohort Studies&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genes, BRCA1/genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Screening/*methods&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Incidence&lt;/KEYWORD&gt;&lt;KEYWORD&gt;London/epidemiology&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammography/methods&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Pedigree&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Physical Examination&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Assessment&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Risk Factors&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11527694&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="27" w:name="__Fieldmark__30_563349056"/><w:r><w:rPr></w:rPr><w:t>[40]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="27"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">.   However, the benefit attributable to finding cases of DCIS (versus early invasive cancers) has not been established.  In a study with longitudinal follow-up, MRI detected nine breast tumors that were missed by the other screening modalities </w:t></w:r><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Warner&lt;/Author&gt;&lt;Year&gt;2004&lt;/Year&gt;&lt;RecNum&gt;683&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;ACCESSION_NUMBER&gt;15367553&lt;/ACCESSION_NUMBER&gt;&lt;VOLUME&gt;292&lt;/VOLUME&gt;&lt;NUMBER&gt;11&lt;/NUMBER&gt;&lt;YEAR&gt;2004&lt;/YEAR&gt;&lt;DATE&gt;Sep 15&lt;/DATE&gt;&lt;TITLE&gt;Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination&lt;/TITLE&gt;&lt;PAGES&gt;1317-25&lt;/PAGES&gt;&lt;AUTHOR_ADDRESS&gt;Division of Medical Oncology, Department of Medicine, Sunnybrook and Women&amp;apos;s College Health Sciences Centre and University of Toronto, Ontario, Canada. ellen.warner@sw.ca&lt;/AUTHOR_ADDRESS&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Warner, E.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Plewes, D. B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hill, K. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Causer, P. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Zubovits, J. T.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Jong, R. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Cutrara, M. R.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;DeBoer, G.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Yaffe, M. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Messner, S. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Meschino, W. S.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Piron, C. A.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Narod, S. A.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;SECONDARY_TITLE&gt;Jama&lt;/SECONDARY_TITLE&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;Adult&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Biopsy&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Breast Neoplasms/*diagnosis/*genetics&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Comparative Study&lt;/KEYWORD&gt;&lt;KEYWORD&gt;False Positive Reactions&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Female&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA1&lt;/KEYWORD&gt;&lt;KEYWORD&gt;*Genes, BRCA2&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Genetic Predisposition to Disease&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Humans&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Magnetic Resonance Imaging&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mammography&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Middle Aged&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Mutation&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Physical Examination&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Research Support, Non-U.S. Gov&amp;apos;t&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Sensitivity and Specificity&lt;/KEYWORD&gt;&lt;KEYWORD&gt;Ultrasonography, Mammary&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;URL&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15367553&lt;/URL&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;</w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="28" w:name="__Fieldmark__31_563349056"/><w:r><w:rPr></w:rPr><w:t>[41]</w:t></w:r><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r><w:bookmarkEnd w:id="28"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> .   Of note, only two of the 22 women with breast cancer (9%) detected in this Canadian trial had lymph node metastases</w:t></w:r><w:bookmarkStart w:id="29" w:name="_Ref78127188"/><w:r><w:rPr></w:rPr><w:t>.</w:t></w:r><w:bookmarkEnd w:id="29"/><w:r><w:rPr></w:rPr><w:t xml:space="preserve">  Thus, we feel that MRI has a role in screening </w:t></w:r><w:r><w:rPr><w:i/><w:iCs/></w:rPr><w:t>BRCA</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> mutations carriers.  It is not clear if the addition of mammography to MRI improves the sensitivity of screening. </w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr><w:b/><w:u w:val="single"/></w:rPr></w:pPr><w:r><w:rPr><w:b/><w:u w:val="single"/></w:rPr><w:t>Conclusions</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:tab/><w:t xml:space="preserve">Women with a BRCA1 or BRCA2 mutation represent the highest risks group for the development of breast cancer.  Fortunately, several options are available for women - each option has varying levels of breast cancer risk reduction, in addition to various risks. Prophylactic mastectomy offers the best protection against developing breast cancer, but the majority of women in Canada are unwilling to exercise this option.   The extent of risk reduction associated with tamoxifen and prophylactic oophorectomy are less (approximately 50% risk reduction for each) and are associated with the side effects of hormone withdrawal.   For these reasons, for many women screening is the preferred option.  Screening will not prevent breast cancer from developing; the intention is to detect a tumour at a treatable stage.  Women identified as having a BRCA1 or BRCA2 mutation should be made aware of all of their breast cancer prevention options.  Ultimately, the goal of genetic testing for BRCA1 and BRCA2 is to identify high-risk women so that cancer can be prevented.  </w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:pageBreakBefore/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>References</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:fldChar w:fldCharType="begin"></w:fldChar></w:r><w:r><w:instrText> ADDIN EN.REFLIST </w:instrText></w:r><w:r><w:fldChar w:fldCharType="separate"/></w:r><w:bookmarkStart w:id="30" w:name="__Fieldmark__32_563349056"/><w:r><w:rPr></w:rPr><w:t>1.</w:t><w:tab/><w:t xml:space="preserve">Antoniou, A., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Am J Hum Genet, 2003. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>72</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(5): p. 1117-30.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>2.</w:t><w:tab/><w:t xml:space="preserve">Metcalfe, K., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> J Clin Oncol, 2004. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>22</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(12): p. 2328-35.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>3.</w:t><w:tab/><w:t xml:space="preserve">Verhoog, L.C., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Br J Cancer, 2000. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>83</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(3): p. 384-6.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>4.</w:t><w:tab/><w:t xml:space="preserve">Robson, M., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>BRCA-associated breast cancer in young women.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> J Clin Oncol, 1998. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>16</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(5): p. 1642-9.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>5.</w:t><w:tab/><w:t xml:space="preserve">Claus, E.B., N. Risch, and W.D. Thompson, </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Genetic analysis of breast cancer in the cancer and steroid hormone study.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Am J Hum Genet, 1991. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>48</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(2): p. 232-42.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>6.</w:t><w:tab/><w:t xml:space="preserve">Whittemore, A.S., G. Gong, and J. Itnyre, </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Am J Hum Genet, 1997. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>60</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(3): p. 496-504.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>7.</w:t><w:tab/><w:t xml:space="preserve">Struewing, J.P., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> New England Journal of Medicine, 1997. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>336</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(20): p. 1401-1408.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>8.</w:t><w:tab/><w:t xml:space="preserve">Oddoux, C., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Nature Genetics, 1996. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>14</w:t></w:r><w:r><w:rPr></w:rPr><w:t>: p. 188-190.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>9.</w:t><w:tab/><w:t xml:space="preserve">Thorlacius, S., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Population-based study of risk of breast cancer in carriers of BRCA2 mutation.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Lancet, 1998. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>352</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(9137): p. 1337-9.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>10.</w:t><w:tab/><w:t xml:space="preserve">Gorski, B., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>A high proportion of founder BRCA1 mutations in Polish breast cancer families.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Int J Cancer, 2004. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>110</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(5): p. 683-6.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>11.</w:t><w:tab/><w:t xml:space="preserve">Meijers-Heijboer, M., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> The New England Journal of Medicine, 2001. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>345</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(3): p. 158-164.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>12.</w:t><w:tab/><w:t xml:space="preserve">Rebbeck, T.R., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> J Clin Oncol, 2004. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>22</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(6): p. 1055-62.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>13.</w:t><w:tab/><w:t xml:space="preserve">Metcalfe, K.A., J.L. Semple, and S.A. Narod, </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Time to reconsider subcutaneous mastectomy for breast-cancer prevention?</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Lancet Oncol, 2005. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>6</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(6): p. 431-4.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>14.</w:t><w:tab/><w:t xml:space="preserve">Levine, D.A. and M.L. Gemignani, </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Prophylactic surgery in hereditary breast/ovarian cancer syndrome.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Oncology (Williston Park), 2003. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>17</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(7): p. 932-41; discussion 946-8, 950-2.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>15.</w:t><w:tab/><w:t xml:space="preserve">Narod, S.A., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Modifiers of risk of hereditary breast and ovarian cancer.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Nat Rev Cancer, 2002. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>2</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(2): p. 113-23.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>16.</w:t><w:tab/><w:t xml:space="preserve">Kauff, N.D., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> N Engl J Med, 2002. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>346</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(21): p. 1609-15.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>17.</w:t><w:tab/><w:t xml:space="preserve">Rebbeck, T.R., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> J Natl Cancer Inst, 1999. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>91</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(17): p. 1475-9.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>18.</w:t><w:tab/><w:t xml:space="preserve">Rebbeck, T.R., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> N Engl J Med, 2002. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>346</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(21): p. 1616-22.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>19.</w:t><w:tab/><w:t xml:space="preserve">Eisen, A., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> J Clin Oncol, 2005. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>23</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(30): p. 7491-6.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>20.</w:t><w:tab/><w:t xml:space="preserve">Pritchard, K.I., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Breast cancer prevention with selective estrogen receptor modulators: a perspective.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Ann N Y Acad Sci, 2001. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>949</w:t></w:r><w:r><w:rPr></w:rPr><w:t>: p. 89-98.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>21.</w:t><w:tab/><w:t xml:space="preserve">King, M.C., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Jama, 2001. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>286</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(18): p. 2251-6.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>22.</w:t><w:tab/><w:t xml:space="preserve">Gronwald, J., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Int J Cancer, 2006. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>118</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(9): p. 2281-4.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>23.</w:t><w:tab/><w:t xml:space="preserve">Weitzel, J.N., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>A comparison of bilateral breast cancers in BRCA carriers.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Cancer Epidemiol Biomarkers Prev, 2005. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>14</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(6): p. 1534-8.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>24.</w:t><w:tab/><w:t xml:space="preserve">Foulkes, W.D., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Cancer, 2003. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>98</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(8): p. 1569-1577.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>25.</w:t><w:tab/><w:t xml:space="preserve">Burke, W., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Recommendations for follow-up care of individuals with an inherited predisposition to cancer.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> JAMA, 1997. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>277</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(12): p. 997-1003.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>26.</w:t><w:tab/><w:t xml:space="preserve">Eisinger, F., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Ann Oncol, 1998. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>9</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(9): p. 939-50.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>27.</w:t><w:tab/><w:t xml:space="preserve">Pichert, G., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Evidence-based management options for women at increased breast/ovarian cancer risk.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Ann Oncol, 2003. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>14</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(1): p. 9-19.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>28.</w:t><w:tab/><w:t xml:space="preserve">Tilanus-Linthorst, M., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Int J Cancer, 2002. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>102</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(1): p. 91-5.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>29.</w:t><w:tab/><w:t xml:space="preserve">Kerlikowske, K., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Performance of screening mammography among women with and without a first-degree relative with breast cancer.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Ann Intern Med, 2000. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>133</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(11): p. 855-63.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>30.</w:t><w:tab/><w:t xml:space="preserve">Kollias, J., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Screening women aged less than 50 years with a family history of breast cancer.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Eur J Cancer, 1998. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>34</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(6): p. 878-83.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>31.</w:t><w:tab/><w:t xml:space="preserve">Goffin, J., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> J Natl Cancer Inst, 2001. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>93</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(22): p. 1754-5.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>32.</w:t><w:tab/><w:t xml:space="preserve">Scheuer, L., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> J Clin Oncol, 2002. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>20</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(5): p. 1260-8.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>33.</w:t><w:tab/><w:t xml:space="preserve">Brekelmans, C.T., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> J Clin Oncol, 2001. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>19</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(4): p. 924-30.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>34.</w:t><w:tab/><w:t xml:space="preserve">Tilanus-Linthorst, M.M., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>First experiences in screening women at high risk for breast cancer with MR imaging.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Breast Cancer Res Treat, 2000. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>63</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(1): p. 53-60.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>35.</w:t><w:tab/><w:t xml:space="preserve">Stoutjesdijk, M.J., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> J Natl Cancer Inst, 2001. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>93</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(14): p. 1095-102.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>36.</w:t><w:tab/><w:t xml:space="preserve">Morris, E.A., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>MRI of occult breast carcinoma in a high-risk population.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> AJR Am J Roentgenol, 2003. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>181</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(3): p. 619-26.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>37.</w:t><w:tab/><w:t xml:space="preserve">Kriege, M., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> N Engl J Med, 2004. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>351</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(5): p. 427-37.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>38.</w:t><w:tab/><w:t xml:space="preserve">Liberman, L., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Probably benign lesions at breast magnetic resonance imaging: preliminary experience in high-risk women.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Cancer, 2003. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>98</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(2): p. 377-88.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>39.</w:t><w:tab/><w:t xml:space="preserve">Robson, M.E. and K. Offit, </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Breast MRI for women with hereditary cancer risk.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Jama, 2004. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>292</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(11): p. 1368-70.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>40.</w:t><w:tab/><w:t xml:space="preserve">Gui, G.P., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography?</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Eur J Cancer, 2001. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>37</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(13): p. 1668-73.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t>41.</w:t><w:tab/><w:t xml:space="preserve">Warner, E., et al., </w:t></w:r><w:r><w:rPr><w:i/></w:rPr><w:t>Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.</w:t></w:r><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> Jama, 2004. </w:t></w:r><w:r><w:rPr><w:b/></w:rPr><w:t>292</w:t></w:r><w:r><w:rPr></w:rPr><w:t>(11): p. 1317-25.</w:t></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:rPr></w:rPr></w:pPr><w:bookmarkStart w:id="31" w:name="__Fieldmark__32_563349056"/><w:bookmarkEnd w:id="31"/><w:r><w:rPr></w:rPr></w:r><w:r><w:fldChar w:fldCharType="end"/></w:r></w:p><w:p><w:pPr><w:pStyle w:val="Normal"/><w:spacing w:lineRule="auto" w:line="480"/><w:ind w:left="720" w:right="0" w:hanging="720"/><w:rPr></w:rPr></w:pPr><w:r><w:rPr></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:sectPr><w:footerReference w:type="default" r:id="rId2"/><w:type w:val="nextPage"/><w:pgSz w:w="12240" w:h="15840"/><w:pgMar w:left="1080" w:right="1080" w:header="0" w:top="1080" w:footer="720" w:bottom="1080" w:gutter="0"/><w:pgNumType w:start="1" w:fmt="decimal"/><w:formProt w:val="false"/><w:textDirection w:val="lrTb"/><w:docGrid w:type="default" w:linePitch="360" w:charSpace="0"/></w:sectPr></w:body></w:document>